Tri Locum Partners’s Kyntra Bio KYNB Stock Holding History

Tri Locum Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,900	Closed	-$331K	–	69
2023 Q2	$331K	Buy	+4,900	New	+$2.03M	0.12%	45

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's KYNB Position: Q4 2022 in Review

Tri Locum Partners sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 2,974 shares — an estimated $967K sold.

Tri Locum Partners first reported a position in KYNB in Q3 2022 and held it in 1 quarter. The position peaked at $967K in Q3 2022. 144 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

Tri Locum Partners reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
Tri Locum Partners sold 2,974 Kyntra Bio shares in Q4 2022, an estimated $967K.
Tri Locum Partners first reported a position in Kyntra Bio in Q3 2022 and held it in 1 quarter.
Tri Locum Partners's Kyntra Bio position peaked at $967K in Q3 2022.
144 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.